[General practice-field trials of Linctifed with 17871 patients with inflammatory diseases of the respiratory tract].
D000284:Administration, Oral; D000293:Adolescent; D000996:Antitussive Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003061:Codeine / Q000008:administration & dosage* / Q000031:analogs & derivatives; D004338:Drug Combinations; D004809:Ephedrine / Q000008:administration & dosage*; D005069:Evaluation Studies as Topic; D005100:Expectorants / Q000008:administration & dosage*; D006140:Guaifenesin / Q000008:administration & dosage*; D006634:Histamine H1 Antagonists / Q000008:administration & dosage*; D006801:Humans; D007223:Infant; D054199:Pseudoephedrine; D011725:Pyridines / Q000008:administration & dosage*; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D014311:Triprolidine / Q000008:administration & dosage*
D000996:Antitussive Agents; D004338:Drug Combinations; D005100:Expectorants; D006634:Histamine H1 Antagonists; D011725:Pyridines; D014311:Triprolidine; D006140:Guaifenesin; C022253:linctifed; D054199:Pseudoephedrine; D004809:Ephedrine; D003061:Codeine
Prüfung von Linctifed im Praxis-Feldversuch an 17871 Patienten mit entzündlichen erkrankungen der Atemwege.